In a report released yesterday, Joseph Thome from TD Cowen maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report). The ...

Thome covers the Healthcare sector, focusing on stocks such as Alkermes, Jazz Pharmaceuticals ... Intellia Therapeutics (NTLA) Company Description: Intellia Therapeutics, Inc. engages in the ...

Prior to Rectify, she was Chief Financial Officer at Akouos, Inc., where she led corporate finance ... compared to amounts ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing ...

Aigen Investment Management LP purchased a new stake in Alkermes plc (NASDAQ:ALKS – Free Report) during the 3rd quarter, ...

Alkermes (NASDAQ:ALKS – Free Report) had its target price upped by Mizuho from $35.00 to $40.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has an outperform ...

Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed its forecast and conducted a sum-of-the-parts analysis.

Mergers and acquisitions are expected to increase under a Republican president, especially as President-elect Donald Trump is ...

As a result, Seeking Alpha screened a list of stocks that fit the mold for the above requirements, and found only 10 names.

Velocity One, a newly formed aerospace manufacturing holding company, announced the acquisition of Emcore Corp. for $31.4 ...